Nasdaq · CIK 0001721484
LGVN Longeveron Inc.
Insider trading from SEC Form 4. Last filing 8 d ago. Close $2.48 on Oct 9, 2026, +6% from the 52-week low and -79% from the high.
Longeveron Inc. (LGVN) has 56 SEC Form 4 filings on file from 16 insiders, the latest filed on Oct 5, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
4 open-market trades have been scored at LGVN. The newest: Rock Soffer (director) sold $27k of stock on May 29, 2025, filed Jun 2, 2025, scored 28 (weak). 2 insiders sold within 14 days of each other around May 29, 2025.
LGVN closed at $2.48 on Oct 9, 2026, 6% above its 52-week low and 79% below its 52-week high.
3 Form 144 notices of planned sales are on file, the latest filed May 29, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Longeveron Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 28Weak | Rock Soffer director sell | $27k 21,000 shares | -9% | +4% from low-43% from high | |
| 23Weak | Rock Soffer director sell | $2,640 2,000 shares | -1% | +9% from low-40% from high | |
| 23Weak | Joshua Hare Chief Scientific Officer sell | $7,367 5,250 shares | -1% | +13% from low-38% from high | |
| 15Weak | Khoso Baluch director sell | $2,588 1,250 shares | -5% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 29, 2025 | Rock Soffer Director | 21,000 0.16% of outstanding | $27k | May 29, 2025 | none |
| May 15, 2025 | Hare Joshua Officer, Director | 5,250 0.04% of outstanding | $7,220 | May 15, 2025 | none |
| Nov 27, 2024 | Baluch Khoso Director | 1,250 0.01% of outstanding | $2,575 | Nov 27, 2024 | none |
Transactions
The newest 50 of 69 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Devin Blass CTO & SVP of CMC | FTax withholding Class A Common Stock | -2,520 | $2.59 | $6,527 | 68,653 | 8 d ago |
| Oct 1, 2026 | Paul T Lehr General Counsel, Secretary | FTax withholding Class A Common Stock | -2,253 | $2.59 | $5,835 | 83,889 | 8 d ago |
| Oct 1, 2026 | Nirav S. Jhaveri Chief Financial Officer | FTax withholding Class A Common Stock | -742 | $2.59 | $1,922 | 29,258 | 8 d ago |
| Oct 1, 2026 | Nataliya Agafonova Chief Medical Officer | FTax withholding Class A Common Stock | -2,913 | $2.59 | $7,545 | 68,778 | 8 d ago |
| Oct 1, 2026 | Stephen H Willard Chief Executive Officer | FTax withholding Class A Common Stock | -1,987 | $2.59 | $5,146 | 74,916 | 8 d ago |
| May 1, 2026 | Nataliya Agafonova Chief Medical Officer | AGrant or award Class A Common Stock | +250,000 | $0.00 | $0 | 453,419 | May 5, 2026 |
| May 1, 2026 | Devin Blass CTO & SVP of CMC | AGrant or award Class A Common Stock | +250,000 | $0.00 | $0 | 441,543 | May 5, 2026 |
| Apr 1, 2026 | Nataliya Agafonova Chief Medical Officer | FTax withholding Class A Common Stock | -13,145 | $1.12 | $15k | 203,419 | Apr 3, 2026 |
| Apr 1, 2026 | Devin Blass CTO & SVP of CMC | FTax withholding Class A Common Stock | -8,633 | $1.12 | $9,669 | 191,543 | Apr 3, 2026 |
| Mar 2, 2026 | Stephen H Willard Chief Executive Officer | AGrant or award Class A Common Stock | +200,000 | $0.00 | $0 | 200,000 | Mar 13, 2026 |
| Mar 2, 2026 | Stephen H Willard Chief Executive Officer | FTax withholding Class A Common Stock | -105,533 | $0.55 | $58k | 94,467 | Mar 13, 2026 |
| Mar 2, 2026 | Stephen H Willard Chief Executive Officer | AGrant or award Class A Common Stock | +200,000 | $0.00 | $0 | 294,467 | Mar 13, 2026 |
| Mar 2, 2026 | Stephen H Willard Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Mar 13, 2026 |
| Jan 2, 2026 | Paul T Lehr General Counsel, Secretary | FTax withholding Class A Common Stock | -6,952 | $0.59 | $4,123 | 344,177 | Jan 6, 2026 |
| Jan 2, 2026 | Lisa Locklear Chief Financial Officer | FTax withholding Class A Common Stock | -10,250 | $0.59 | $6,078 | 228,831 | Jan 6, 2026 |
| Jan 2, 2026 | James Nathaniel Powell Chief Executive Officer | FTax withholding Class A Common Stock | -2,464 | $0.59 | $1,461 | 125,593 | Jan 6, 2026 |
| Jan 2, 2026 | Nataliya Agafonova Chief Medical Officer | FTax withholding Class A Common Stock | -10,250 | $0.59 | $6,078 | 216,564 | Jan 6, 2026 |
| Jan 2, 2026 | Devin Blass CTO & SVP of CMC | FTax withholding Class A Common Stock | -10,700 | $0.59 | $6,345 | 200,176 | Jan 6, 2026 |
| Oct 1, 2025 | George A. Paletta Jr. director | AGrant or award Class A Common Stock | +34,000 | $0.00 | $0 | 34,000 | Oct 27, 2025 |
| Oct 1, 2025 | Nataliya Agafonova Chief Medical Officer | FTax withholding Class A Common Stock | -11,883 | $0.74 | $8,822 | 226,814 | Oct 3, 2025 |
| Oct 1, 2025 | Devin Blass CTO & SVP of CMC | FTax withholding Class A Common Stock | -7,609 | $0.74 | $5,649 | 210,876 | Oct 3, 2025 |
| Oct 1, 2025 | Paul T Lehr General Counsel, Secretary | FTax withholding Class A Common Stock | -4,944 | $0.74 | $3,670 | 351,129 | Oct 3, 2025 |
| Oct 1, 2025 | Lisa Locklear Chief Financial Officer | FTax withholding Class A Common Stock | -11,883 | $0.74 | $8,822 | 239,081 | Oct 3, 2025 |
| Oct 1, 2025 | James Nathaniel Powell Chief Executive Officer | FTax withholding Class A Common Stock | -2,389 | $0.74 | $1,774 | 128,057 | Oct 3, 2025 |
| Sep 4, 2025 | James Nathaniel Powell Chief Executive Officer | AGrant or award Class A Common Stock | +50,000 | $0.00 | $0 | 130,446 | Oct 1, 2025 |
| Sep 4, 2025 | James Nathaniel Powell Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Oct 1, 2025 |
| Aug 11, 2025 | Khoso Baluch director | POpen-market purchase Class A Common Stock | +11,766 | - | - | 52,516 | Aug 13, 2025 |
| Aug 11, 2025 | Lisa Locklear Chief Financial Officer | POpen-market purchase Class A Common Stock | +11,766 | - | - | 250,964 | Aug 13, 2025 |
| Aug 11, 2025 | Khoso Baluch director | POpen-market purchase Warrant (right to buy)derivative | +29,415 | - | - | 29,415 | Aug 13, 2025 |
| Aug 11, 2025 | Lisa Locklear Chief Financial Officer | POpen-market purchase Warrant (right to buy)derivative | +29,415 | - | - | 29,415 | Aug 13, 2025 |
| Jul 15, 2025 | Khoso Baluch director | AGrant or award Class A Common Stock | +17,000 | $0.00 | $0 | 40,750 | Jul 17, 2025 |
| Jul 15, 2025 | Devin Blass CTO & SVP of CMC | AGrant or award Class A Common Stock | +102,000 | $0.00 | $0 | 218,485 | Jul 17, 2025 |
| Jul 15, 2025 | Roger Joseph Hajjar director | AGrant or award Class A Common Stock | +17,000 | $0.00 | $0 | 33,000 | Jul 17, 2025 |
| Jul 15, 2025 | Joshua Hare Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +109,000 | $0.00 | $0 | 109,000 | Jul 17, 2025 |
| Jul 15, 2025 | Mohamed Wa'el Ahmed Hashad Chief Executive Officer | AGrant or award Class A Common Stock | +180,000 | $0.00 | $0 | 420,904 | Jul 17, 2025 |
| Jul 15, 2025 | Richard N Kender director | AGrant or award Class A Common Stock | +17,000 | $0.00 | $0 | 33,000 | Jul 17, 2025 |
| Jul 15, 2025 | Paul T Lehr General Counsel, Secretary | AGrant or award Class A Common Stock | +102,000 | $0.00 | $0 | 356,073 | Jul 17, 2025 |
| Jul 15, 2025 | Lisa Locklear Chief Financial Officer | AGrant or award Class A Common Stock | +102,000 | $0.00 | $0 | 239,198 | Jul 17, 2025 |
| Jul 15, 2025 | Ursula Ungaro director | AGrant or award Class A Common Stock | +17,000 | $0.00 | $0 | 41,000 | Jul 17, 2025 |
| Jul 15, 2025 | Neha J. Motwani director | AGrant or award Class A Common Stock | +17,000 | $0.00 | $0 | 33,000 | Jul 17, 2025 |
| Jul 15, 2025 | Rock Soffer director | AGrant or award Class A Common Stock | +17,000 | $0.00 | $0 | 226,034 | Jul 17, 2025 |
| Jul 15, 2025 | Nataliya Agafonova Chief Medical Officer | AGrant or award Class A Common Stock | +102,000 | $0.00 | $0 | 238,697 | Jul 17, 2025 |
| Jul 15, 2025 | Nataliya Agafonova Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +34,000 | $0.00 | $0 | 34,000 | Jul 17, 2025 |
| Jul 15, 2025 | Devin Blass CTO & SVP of CMC | AGrant or award Stock Option (right to buy)derivative | +34,000 | $0.00 | $0 | 34,000 | Jul 17, 2025 |
| Jul 15, 2025 | Mohamed Wa'el Ahmed Hashad Chief Executive Officer | AGrant or award Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 60,000 | Jul 17, 2025 |
| Jul 15, 2025 | Paul T Lehr General Counsel, Secretary | AGrant or award Stock Option (right to buy)derivative | +34,000 | $0.00 | $0 | 34,000 | Jul 17, 2025 |
| Jul 15, 2025 | Lisa Locklear Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +34,000 | $0.00 | $0 | 34,000 | Jul 17, 2025 |
| Jul 1, 2025 | Nataliya Agafonova Chief Medical Officer | FTax withholding Class A Common Stock | -7,431 | $1.28 | $9,512 | 136,697 | Jul 3, 2025 |
| Jul 1, 2025 | Devin Blass CTO & SVP of CMC | FTax withholding Class A Common Stock | -4,599 | $1.28 | $5,887 | 116,485 | Jul 3, 2025 |
| Jul 1, 2025 | Joshua Hare Chief Scientific Officer | AGrant or award Stock Option (right to buy)derivative | +49,219 | $0.00 | $0 | 49,219 | Jul 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Nataliya AgafonovaChief Medical Officer
- Khoso Baluchdirector
- Devin BlassCTO & SVP of CMC
- Roger Joseph Hajjardirector
- Joshua HareChief Scientific Officer
- Mohamed Wa'el Ahmed HashadChief Executive Officer
- Nirav S. JhaveriChief Financial Officer
- Richard N Kenderdirector, officer
- Paul T LehrGeneral Counsel, Secretary
- Lisa LocklearChief Financial Officer
- Neha J. Motwanidirector
- George A. Paletta Jr.director
- James Nathaniel PowellChief Executive Officer
- Rock Sofferdirector
- Ursula Ungarodirector
- Stephen H WillardChief Executive Officer
Questions about LGVN
Answered from the filings on this page, as of the latest one.
Are insiders buying LGVN?
No. In the last 90 days no insider at Longeveron Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade LGVN on the open market?
Rock Soffer (director) sold $27k of LGVN on May 29, 2025 and filed the Form 4 on Jun 2, 2025. InsiderTell scored 28 (weak), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Longeveron Inc.?
16 people have filed a Form 4 at Longeveron Inc., among them Nataliya Agafonova (Chief Medical Officer), Khoso Baluch (director), Devin Blass (CTO & SVP of CMC). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.